Despite the advent of targeted therapies and the associated rise in the use of companion and complementary diagnostics, we are only just emerging from the initial exploratory stages of oncology biomarker testing. As will be argued in this paper, we are on the cusp of a much more radical revolution, and the molecular diagnostics landscape is set to change dramatically in the coming decades. It is crucial that any company entering this space prepare for this imminent upheaval and plan their launch strategy accordingly.
A challenge that market research is increasingly facing is why, in a world where behavioural science apparently suggests that are limits to what consumers tell us, do we continue to ask questions?
The everyday concerns of the global population are the focus of one of Ipsos’ flagship global surveys. Each month we ask an online sample of over 18,000 citizens in more than 25 countries1 about the key issues they believe are facing their country, asking them to pick up to three from a diverse array of topics, ranging from unemployment to access to credit.
In an era where politics often overtakes the best cared-for brands, how do responsible stewards prepare their organisations to navigate ideological consumers?
The pace of technological and social change is bewilderingly fast. In the world of brand and communications, we feel this particularly keenly, with the digital revolution transforming the way that brands seek to connect with people.
“Fake news”, according to Wikipedia, is “written and published with the intent to mislead in order to gain financially or politically, often with sensationalist, exaggerated or patently false headlines that grab attention.”
The South Africa Primary Consumer Sentiment (“Consumer Confidence”) Index (“PCSI”) as measured by the Thomson Reuters/Ipsos PCSI for June,2017 is down 1.2 percentage points over last month.
